323.2 𩺠åèç
323.2.1 é«é »èé»
323.2.1.1 Influenza
- A/B/C, A and B clinically relevant
- Antigenic drift (seasonal), shift (pandemic)
- Oseltamivir 75 BID Ã 5 d (within 48 hr ideal)
- Baloxavir single dose alternative
- Annual vaccine
323.2.1.2 Post-Influenza Bacterial Pneumonia
- S. aureus (often MRSA, PVL+)
- S. pneumoniae
- Severe cavitating
- Vancomycin + standard CAP
323.2.1.3 COVID-19 Treatments
- Paxlovid (nirmatrelvir/ritonavir) outpatient high-risk
- Dexamethasone (RECOVERY) if requires O2
- Tocilizumab + baricitinib (REMAP-CAP) severe + â inflammation
- Remdesivir for hospitalized on O2
323.2.2 ææ··æ·æ¯èŒ
| Virus | Season | Severity | Treatment |
|---|---|---|---|
| Influenza | Winter | Variable; severe in elderly | Oseltamivir, baloxavir |
| RSV | Winter | Severe in elderly, infants | Supportive; nirsevimab infants |
| COVID-19 | Year-round | Variable | Paxlovid (outpatient), dexamethasone (severe) |
| MERS | Sporadic | High mortality | Supportive |
| Hantavirus | Rodent exposure | High mortality | Supportive |
| Measles | Unvaccinated | Severe in immunocompromised | Supportive, vitamin A |